Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study Evaluating Combination Therapy With the Receptor Tyrosine Kinase Inhibitor PLX3397 and Sirolimus in Patients With Unresectable Sarcoma and Phase II Study in Malignant Peripheral Nerve Sheath Tumors

Next Previous
Search
Trial Profile

Phase I Study Evaluating Combination Therapy With the Receptor Tyrosine Kinase Inhibitor PLX3397 and Sirolimus in Patients With Unresectable Sarcoma and Phase II Study in Malignant Peripheral Nerve Sheath Tumors

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 26 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pexidartinib (Primary) ; Sirolimus
  • Indications Angiomyolipoma; Gastrointestinal stromal tumours; Giant cell tumour of tendon sheath; Leiomyosarcoma; Meningioma; Nerve sheath neoplasms; Neurofibromatoses; Sarcoma; Soft tissue sarcoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms PLX3397

Most Recent Events

  • 21 Mar 2025 Status changed from active, no longer recruiting to discontinued.
  • 04 Jun 2024 Results assessing safety and efficacy of of the combination of pexidartinib and sirolimus to target tumor-associated macrophages in unresectable malignant peripheral nerve sheath tumors presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 12 Mar 2024 Planned End Date changed from 1 Mar 2024 to 1 Jun 2024.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top